A new targeted antibody treatment for ovarian cancer
A novel targeted antibody therapeutic to treat ovarian cancer
['FUNDING_SBIR_1'] · TRIO PHARMACEUTICALS INC. · NIH-10820095
This study is testing a new treatment for ovarian cancer that helps your immune system fight the disease better by targeting harmful cells in the tumor, and it's designed for women who haven't had success with regular chemotherapy.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TRIO PHARMACEUTICALS INC. (nih funded) |
| Locations | 1 site (MURRIETA, UNITED STATES) |
| Trial ID | NIH-10820095 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a targeted antibody therapeutic specifically designed to treat ovarian cancer, which is a leading cause of cancer deaths among women. The approach aims to enhance the immune system's ability to fight tumors by selectively targeting and eliminating immunosuppressive cells in the tumor microenvironment, while also attacking cancer cells. By addressing the limitations of current immuno-oncology drugs, this research seeks to provide a more effective treatment option for patients who have not responded well to traditional chemotherapy. The study will involve clinical trials to evaluate the safety and efficacy of this novel therapeutic.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer who have not responded adequately to existing chemotherapy treatments.
Not a fit: Patients with early-stage ovarian cancer or those who have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for ovarian cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While immuno-oncology approaches have shown promise in other cancers, this specific targeted antibody therapeutic represents a novel approach that has not yet been tested in clinical settings for ovarian cancer.
Where this research is happening
MURRIETA, UNITED STATES
- TRIO PHARMACEUTICALS INC. — MURRIETA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAUS, REINER — TRIO PHARMACEUTICALS INC.
- Study coordinator: LAUS, REINER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, Cancers